Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 727 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer July 2, 2026 Get the Facts Before Using Online Information May 11, 2022 Former WNBA Player, Current Georgia Tech Coach Tasha Butts Diagnosed with... December 14, 2021 6 Things That Helped Me Think Positively During Cancer: A Patient... August 16, 2022 Load more HOT NEWS ¿Ahora qué? 10 maneras de adaptarse a la vida cotidiana después... Beloved Kansas City Jazz Singer Passes Away at 48 After 13-Year... EMA Recommends Granting a Marketing Authorisation for Melphalan A Better Biomarker for Cancer Immunotherapy?
